From tumor microenvironment orchestrators to actionable targets: a systematic review of TAM-targeted therapies in triple-negative breast cancer.

Prior response to anti-VEGF agents predicts the efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer.

Clinical utility of comprehensive genomic profiling in thoracic malignancies beyond conventional gene testing.

A phase 1 dose-finding and pharmacokinetic study of acasunlimab alone or in combination with pembrolizumab in Japanese patients with advanced or metastatic solid tumors.

Correction: Prevention of hepatitis B virus reactivation according to hepatitis B surface antigen status in patients receiving systemic chemotherapy in Japan using an electronic medical record database.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; camizestrant for breast cancer, ivosidenib for biliary tract cancer, subcutaneous isatuximab and talquetamab plus teclistamab for multiple myeloma, isotretinoin for neuroblastoma, selpercatinib for pediatric RET-altered tumors, tafasitamab for lymphoma, and tislelizumab and durvalumab for gastric cancer.

From tumor microenvironment orchestrators to actionable targets: a systematic review of TAM-targeted therapies in triple-negative breast cancer.

Prior response to anti-VEGF agents predicts the efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer.

Clinical utility of comprehensive genomic profiling in thoracic malignancies beyond conventional gene testing.

A phase 1 dose-finding and pharmacokinetic study of acasunlimab alone or in combination with pembrolizumab in Japanese patients with advanced or metastatic solid tumors.

Correction: Prevention of hepatitis B virus reactivation according to hepatitis B surface antigen status in patients receiving systemic chemotherapy in Japan using an electronic medical record database.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; camizestrant for breast cancer, ivosidenib for biliary tract cancer, subcutaneous isatuximab and talquetamab plus teclistamab for multiple myeloma, isotretinoin for neuroblastoma, selpercatinib for pediatric RET-altered tumors, tafasitamab for lymphoma, and tislelizumab and durvalumab for gastric cancer.